Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism

M. J. Zigmond, A. L. Acheson, M. K. Stachowiak and E. M. Stricker

Parkinson's disease usually involves a lengthy preclinical period during which few neurological symptoms are observed despite extensive damage to the dopaminergic nigrostriatal bundle. Injury to this projection in the rat also fails to produce major neurological dysfunctions. In our studies, damage to the nigrostriatal bundle of the rat, resulting in the loss of up to 95% of the dopaminergic terminals in striatum, was accompanied by apparent increases in the synthesis and release of dopamine (DA) from those dopaminergic terminals that remained. More specifically, both the activity of the rate-limiting biosynthetic enzyme, tyrosine hydroxylase, and the content of the principal DA metabolite, dihydroxyphenylacetic acid, were increased in striatum relative to DA levels. The increases were exponentially related to DA loss.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery
Mounayar et al.
Brain 2007;130:2898-2914.
ABSTRACT | FULL TEXT  

Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
Quik et al.
J. Neurosci. 2006;26:4681-4689.
ABSTRACT | FULL TEXT  

Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study
Goerendt et al.
Brain 2003;126:312-325.
ABSTRACT | FULL TEXT  

Forced Nonuse in Unilateral Parkinsonian Rats Exacerbates Injury
Tillerson et al.
J. Neurosci. 2002;22:6790-6799.
ABSTRACT | FULL TEXT  

The Role of Dopamine Receptors in Regulating the Size of Axonal Arbors
Parish et al.
J. Neurosci. 2001;21:5147-5157.
ABSTRACT | FULL TEXT  

Age-Related Changes in the Capacity, Rate, and Modulation of Dopamine Uptake within the Striatum and Nucleus Accumbens of Fischer 344 Rats: An In Vivo Electrochemical Study
Hebert and Gerhardt
J. Pharmacol. Exp. Ther. 1999;288:879-887.
ABSTRACT | FULL TEXT